These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33181733)

  • 1. 18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient.
    Marafi F; Sasikumar A; Aldaas M; Esmail A
    Clin Nucl Med; 2021 Jan; 46(1):e65-e67. PubMed ID: 33181733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-PSMA 1007 in Suspected Renal Cell Carcinoma.
    Marafi F; Sasikumar A; Al-Terki A; Alfeeli M
    Clin Nucl Med; 2020 May; 45(5):377-378. PubMed ID: 32209880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complimentary Pattern of Uptake in 18F-FDG PET/CT and 68Ga-Prostate-Specific Membrane Antigen PET/CT in a Case of Metastatic Clear Cell Renal Carcinoma.
    Sasikumar A; Joy A; Nanabala R; Unni M; Tk P
    Clin Nucl Med; 2016 Dec; 41(12):e517-e519. PubMed ID: 27749421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
    Sadeq A; Usmani S; Esmail AA; Fathallah W; Alfeeli MA; Marafi F
    Clin Nucl Med; 2022 Jul; 47(7):627-628. PubMed ID: 35675136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 68Ga-PSMA PET/CT and 18F-FDG PET/CT in Renal Cell Carcinoma.
    Chen EJ; Tan TH; Chew MT; Chye PC
    Clin Nucl Med; 2020 Jul; 45(7):e317-e319. PubMed ID: 32404702
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Mittlmeier LM; Unterrainer M; Rodler S; Todica A; Albert NL; Burgard C; Cyran CC; Kunz WG; Ricke J; Bartenstein P; Stief CG; Ilhan H; Staehler M
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2031-2037. PubMed ID: 33369689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
    Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
    Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Qi Z; Yao X; Su M; Huang R
    Hell J Nucl Med; 2023; 26(2):155-156. PubMed ID: 37527052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
    Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
    Has Simsek D; Civan C; Erdem S; Sanli Y
    Clin Nucl Med; 2021 Jul; 46(7):579-581. PubMed ID: 33782292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of
    Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
    J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
    Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
    Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
    Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
    Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Accuracy of
    Sprute K; Kramer V; Koerber SA; Meneses M; Fernandez R; Soza-Ried C; Eiber M; Weber WA; Rauscher I; Rahbar K; Schaefers M; Watabe T; Uemura M; Naka S; Nonomura N; Hatazawa J; Schwab C; Schütz V; Hohenfellner M; Holland-Letz T; Debus J; Kratochwil C; Amaral H; Choyke PL; Haberkorn U; Sandoval C; Giesel FL
    J Nucl Med; 2021 Feb; 62(2):208-213. PubMed ID: 32817141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of
    Hirasawa H; Taketomi-Takahashi A; Katsumata N; Higuchi T; Sekine Y; Suzuki K; Kaneko Y; Hiromura K; Fukushima Y; Tsushima Y
    Jpn J Radiol; 2024 Oct; 42(10):1178-1186. PubMed ID: 38795287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-PSMA 1007 Uptake in a Man With Metastatic Breast Cancer.
    Marafi F; Sasikumar A; Alfeeli M; Thuruthel S
    Clin Nucl Med; 2020 Jun; 45(6):e276-e278. PubMed ID: 32332302
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Parghane RV; Basu S
    J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hürthle Cell Thyroid Adenoma Showing Avid Uptake on 18F-PSMA-1007 PET/CT.
    Tang K; Wang Z; Lin J; Zheng X
    Clin Nucl Med; 2020 Mar; 45(3):223-224. PubMed ID: 31876816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
    Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
    Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.